Evidence map›Paper›PMID 36052219›Full record

ArticleJHEP reports : innovation in hepatology2022

Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D.

Adriana Palom, Ariadna Rando-Segura, Judit Vico, Beatriz Pacín, Elena Vargas, Ana Barreira-Díaz, Francisco Rodríguez-Frías, Mar Riveiro-Barciela, Rafael Esteban, Maria Buti

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 59 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 2 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Review
  7. From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Tobevibart plus elebsiran in hepatitis D: crossing a therapeutic threshold.Translational gastroenterology and hepatology · 2026
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Adriana PalomLiver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Ariadna Rando-SeguraMicrobiology Department, Clinical Laboratories, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Judit VicoLiver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Beatriz PacínMicrobiology Department, Clinical Laboratories, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Elena VargasLiver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Ana Barreira-DíazLiver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Francisco Rodríguez-FríasMicrobiology Department, Clinical Laboratories, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Mar Riveiro-BarcielaLiver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Rafael EstebanLiver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Maria ButiLiver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Universitat Autònoma de Barcelona · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Although EASL guidelines recommend anti-HDV testing in all HBsAg-positive individuals, HDV infection remains an underdiagnosed condition. We describe the impact of an HDV screening program by reflex anti-HDV testing in all HBsAg-positive samples and compare the results before and after its implementation. Methods: In total, 2,236 HBsAg-positive determinations were included from January 2018 to December 2021. Only the first sample from each participant was evaluated: 1,492 samples before reflex anti-HDV testing (2018-2020) and 744 samples after (2021). Demographic and clinical characteristics of anti-HDV-positive patients were collected. Results: Before reflex testing, anti-HDV had been tested in 7.6% (114/1492) of HBsAg-positive individuals: 23% (91/390) attended in an academic hospital and only 2% (23/1,102) in primary care centres. After reflex testing was established, 93% (691/744) of HBsAg-positive cases were evaluated for anti-HDV: 91% (533/586) in the academic hospital and 100% (158/158) in primary care. The anti-HDV-positive prevalence was similar before and after reflex testing: 9.6% (11/114) and 8.1% (56/691), respectively. However, the absolute number of anti-HDV-positive patients increased. Most anti-HDV-positive patients were young, HBeAg-negative, Caucasian males. HDV-RNA was detectable in 35 (65%) of 54 tested, HBV-DNA was undetectable in 64%, and alanine aminotransferase levels were normal in 48%. Conclusions: Anti-HDV reflex testing quintupled the absolute number of diagnoses of chronic hepatitis D infection. Before the reflex test, a large percentage of HBsAg-positive individuals had not undergone any anti-HDV determination. Implementation of reflex testing increases the diagnosis of patients with chronic hepatitis D. Lay summary: Chronic hepatitis delta (CHD) is a viral disease caused by HDV, which requires the presence of HBV to propagate. HDV infection can cause rapid progression to cirrhosis, among other severe complications. The prevalence of CHD worldwide is controversial, and the infection often goes unrecognised, mainly because of unawareness among physicians. Use of reflex testing in other viral hepatitis has proven to increase detection and linking-to-care of infected patients. Implementation of anti-HDV testing in all HBsAg-positive patients has led to a 5-fold increase in the number of HDV diagnoses in an academic hospital and primary care centres.

Indexed as

AASLD, American Association for the Study of Liver DiseasesALT, alanine aminotransferaseAnti-HDV reflex testingAnti-HDV screeningAPASL, Asian-Pacific Association for the Study of the LiverAPRI, AST to platelet ratio indexAST, aspartate aminotransferaseChronic hepatitis DFIB-4, fibrosis-4GGT, gamma glutamyl transferaseHDV diagnosisPWID, people who inject drugs

Identifiers

PMID36052219
PMCPMC9425021
OpenAlexW4286515280

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.